"Novel roles of the TRPC3 channel in macrophage functions: implications in atherosclerosis"

“TRPC3 通道在巨噬细胞功能中的新作用:对动脉粥样硬化的影响”

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Atherosclerosis is the main cause of coronary and carotid artery disease and a leading cause of morbidity/mortality in the United States. Ischemic symptoms due to advanced stenosis or thromboembolic events that follow plaque rupture are major clinical manifestations of the disease. Efforts in the field are aimed at reducing plaque progression, improve stability of advanced plaques or stimulate plaque regression. The particular impact that macrophage apoptosis and migration have in advanced lesions is subject of intensive research efforts. Yet, their potential applicability to human pathology is still under debate. Definitions can be achieved by acknowledging the distinctive impact of macrophage diversity in plaque composition and fate, and by exploring molecular components that may selectively affect a macrophage type and not others. The long term goal of this proposal is to examine the contribution of macrophage Transient Receptor Potential Canonical 3 (TRPC3) to these mechanisms in the context of atherosclerosis. In recent work we showed that advanced plaques in ApoE knockout mice with bone marrow deletion of TRPC3 have less necrosis and macrophage apoptosis than controls, and bone marrow derived macrophages from mice with macrophage-specific deletion of TRPC3 (MacTRPC3KO) and differentiated in vitro to the M1 type, have reduced ER stress-induced apoptosis. Remarkably, M2 macrophages were not affected. Our preliminary studies in MacTRPC3KOApoEKO mice show that, compared to controls, advanced plaques have reduced macrophage content and that TRPC3 deletion promotes a reduction in M1/M2 ratios, and decreased apoptosis. We have also found that TRPC3 deficient M1, but not M2 macrophages, have augmented in vitro migration. The general hypothesis is that by virtue of its roles in mechanisms associated to apoptosis and migration of M1 macrophages TRPC3 can exert profound effects on the characteristics of plaque composition and integrity. It is anticipated that suppression of macrophage TRPC3 in vivo will lessen cellularity and necrosis of advanced plaques and favor regressive conditions. In specific aim 1 we will examine the impact of TRPC3 expression and constitutive function on inflammatory signaling and migration of polarized macrophages under conditions of ER stress. In specific aim 2 we will study the impact of macrophage-specific loss or gain of TRPC3 function on the characteristics of atherosclerotic lesions in a mouse model of the disease. In specific aim 3 we will examine the impact of macrophage-specific loss or gain of TRPC3 function on macrophage migration and plaque regression in mouse models of the disease.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Guillermo Vazquez其他文献

Guillermo Vazquez的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Guillermo Vazquez', 18)}}的其他基金

TRPC3 Channels in Molecular and Cellular Events of Atherogenesis
动脉粥样硬化分子和细胞事件中的 TRPC3 通道
  • 批准号:
    8583340
  • 财政年份:
    2011
  • 资助金额:
    $ 37.88万
  • 项目类别:
TRPC3 Channels in Molecular and Cellular Events of Atherogenesis
动脉粥样硬化分子和细胞事件中的 TRPC3 通道
  • 批准号:
    8221944
  • 财政年份:
    2011
  • 资助金额:
    $ 37.88万
  • 项目类别:
TRPC3 Channels in Molecular and Cellular Events of Atherogenesis
动脉粥样硬化分子和细胞事件中的 TRPC3 通道
  • 批准号:
    8399042
  • 财政年份:
    2011
  • 资助金额:
    $ 37.88万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 37.88万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 37.88万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 37.88万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 37.88万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 37.88万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 37.88万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 37.88万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 37.88万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 37.88万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 37.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了